SPPAM
CRSP icon

Summit Partners Public Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

Summit Partners Public Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-125,000
Closed -$5.12M – 79
2019
Q3 		$5.12M Buy
+125,000
New +$5.97M 0.5% 70

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Summit Partners Public Asset Management's CRSP Position: Q4 2019 in Review

Summit Partners Public Asset Management sold out of CRISPR Therapeutics (CRSP) in Q4 2019, closing a stake of 125,000 shares — an estimated $5.12M sold.

Summit Partners Public Asset Management first reported a position in CRSP in Q3 2019 and held it in 1 quarter. The position peaked at $5.12M in Q3 2019. 253 funds tracked by Wall St. Rank hold CRSP as of Q4 2019.

  • Summit Partners Public Asset Management reported no remaining CRISPR Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Summit Partners Public Asset Management sold 125,000 CRISPR Therapeutics shares in Q4 2019, an estimated $5.12M.
  • Summit Partners Public Asset Management first reported a position in CRISPR Therapeutics in Q3 2019 and held it in 1 quarter.
  • Summit Partners Public Asset Management's CRISPR Therapeutics position peaked at $5.12M in Q3 2019.
  • 253 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2019.

Based on Summit Partners Public Asset Management's 13F filing for Q4 2019, filed 14 Feb 2020.